Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $160.5 million.

  • Prime Medicine's Shares Outstanding (Weighted Average) rose 3401.59% to $160.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.5 million, marking a year-over-year increase of 3401.59%. This contributed to the annual value of $118.6 million for FY2024, which is 3037.4% up from last year.
  • Per Prime Medicine's latest filing, its Shares Outstanding (Weighted Average) stood at $160.5 million for Q3 2025, which was up 3401.59% from $129.2 million recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Shares Outstanding (Weighted Average) peaked at $160.5 million during Q3 2025, and registered a low of $13.0 million during Q4 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $91.0 million (2023), whereas its average is $80.5 million.
  • In the last 5 years, Prime Medicine's Shares Outstanding (Weighted Average) soared by 36752.28% in 2023 and then skyrocketed by 838.76% in 2025.
  • Over the past 5 years, Prime Medicine's Shares Outstanding (Weighted Average) (Quarter) stood at $13.0 million in 2021, then surged by 161.23% to $33.9 million in 2022, then surged by 168.42% to $91.0 million in 2023, then surged by 30.37% to $118.6 million in 2024, then soared by 35.33% to $160.5 million in 2025.
  • Its last three reported values are $160.5 million in Q3 2025, $129.2 million for Q2 2025, and $130.9 million during Q1 2025.